These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25705565)

  • 21. IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.
    Sehgal M; Zeremski M; Talal AH; Ginwala R; Elrod E; Grakoui A; Li QG; Philip R; Khan ZK; Jain P
    J Interferon Cytokine Res; 2015 Sep; 35(9):698-709. PubMed ID: 26090579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
    Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
    [No Abstract]   [Full Text] [Related]  

  • 23. Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
    de Ruiter PE; Boor PP; de Jonge J; Metselaar HJ; Tilanus HW; Ijzermans JN; Kwekkeboom J; van der Laan LJ
    Transpl Infect Dis; 2015 Oct; 17(5):707-15. PubMed ID: 26250892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
    Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J
    AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.
    Thong VD; Poovorawan K; Tangkijvanich P; Wasitthankasem R; Vongpunsawad S; Poovorawan Y
    Intervirology; 2015; 58(6):373-81. PubMed ID: 27010195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
    Goebel FD; Jablonowski H
    Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antiviral therapy for HCV on lipid levels.
    Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
    Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
    Bedimo R; Kang M; Tebas P; Overton ET; Hollabaugh K; McComsey G; Bhattacharya D; Evans C; Brown TT; Taiwo B
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):325-8. PubMed ID: 26499270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection.
    Shen T; Chen X; Chen Y; Xu Q; Lu F; Liu S
    J Med Virol; 2010 Jul; 82(7):1152-9. PubMed ID: 20513078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
    Bhagani S
    Curr Opin HIV AIDS; 2011 Nov; 6(6):483-90. PubMed ID: 22001893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
    Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
    Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
    Zheng YH; Zhang CY; He Y; Zhou HY; Zou W; Ding PP; Huang L; Li H
    Chin Med J (Engl); 2005 Jul; 118(14):1195-200. PubMed ID: 16117865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M; Camino N; Ramos B; Berdún MA; Barreiro P; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Martín-Carbonero L; Romero M; García-Samaniego J; Soriano V
    Antivir Ther; 2005; 10(5):657-62. PubMed ID: 16152759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon.
    Cicinnati VR; Kang J; Sotiropoulos GC; Hilgard P; Frilling A; Broelsch CE; Gerken G; Beckebaum S
    J Gen Virol; 2008 May; 89(Pt 5):1243-1253. PubMed ID: 18420803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
    Talal AH; LaFleur J; Hoop R; Pandya P; Martin P; Jacobson I; Han J; Korner EJ
    Aliment Pharmacol Ther; 2013 Feb; 37(4):473-81. PubMed ID: 23289640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
    Abdelraheem WM; Hassuna NA; Abuloyoun SM; Abdel Ghany HM; Rizk HA; Abdelwahab SF
    Arch Virol; 2016 Sep; 161(9):2473-80. PubMed ID: 27352267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of hepatitis C in HIV infected and other immunocompromised individuals.
    Seth AK
    Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.